Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 63.99

+4.7%

Oct 31 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (5095)	12/14/2001 10:59:16 PM
From: Sam Citron	Read Replies (1) of 52153

I find [Amgen's market cap] somewhat disturbing. Why so, Peter? Amgen has been an outstanding company and with widespread concerns about dilutive effects of the merger having reduced the share price to 56, I am inclined to think it may be an excellent buy here. It is at strong support on the chart.http://bigcharts.marketwatch.com/quickchart/quickchart.asp?symb=amgn&sid=0&o_symb=amgn&freq=1&time=8 Didn't Sharer promise 20% growth in '02? ML is looking for $1.70 in '03. 33x these forward earnings unreasonable? Sam Citron

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next